Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

[1]  H. Rugo,et al.  Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma , 1999 .

[2]  C. Reading,et al.  Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. , 1998, Cancer research.

[3]  B. Barlogie,et al.  Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. , 1998, Blood.

[4]  A. Guerriero,et al.  Lymphoid reconstitution after autologous PBSC transplantation with FACS-Sorted CD34+ hematopoietic progenitors , 1998 .

[5]  D. Engelhard,et al.  Nosocomial Colonization, Septicemia, and Ilickman/Broviac Catheter‐Related Infections in Bone Marrow Transplant Recipients: A 5‐Year Prospective Study , 1998, Medicine.

[6]  G. Martinelli,et al.  Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. , 1997, Leukemia & lymphoma.

[7]  C Papadimitriou,et al.  The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems , 1997, Bone Marrow Transplantation.

[8]  C. Huber,et al.  Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.

[9]  J. Vose,et al.  Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow , 1997, Bone Marrow Transplantation.

[10]  H. Grosse-wilde,et al.  Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. , 1996, Blood.

[11]  C. Civin,et al.  Highly purified CD34-positive cells reconstitute hematopoiesis. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Goormastic,et al.  Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. , 1996, Bone marrow transplantation.

[13]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[14]  A. Lichtenstein,et al.  Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. , 1996, Bone marrow transplantation.

[15]  R. Holdrinet,et al.  CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells , 1996, British journal of haematology.

[16]  G. Morgan,et al.  Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. , 1996, Bone marrow transplantation.

[17]  G. Martinelli,et al.  Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. , 1996, Blood.

[18]  A. Tsukamoto,et al.  Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells. , 1995, Journal of hematotherapy.

[19]  R. Storb,et al.  T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. , 1995, Bone marrow transplantation.

[20]  B. Barlogie,et al.  Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. , 1995, Blood.

[21]  A. Lichtenstein,et al.  Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. , 1995, Blood.

[22]  H. Goldschmidt,et al.  Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. , 1995, Blood.

[23]  L. Fouillard,et al.  Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. , 1995, Blood.

[24]  S. Jagannath,et al.  Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. , 1995, Blood.

[25]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.

[26]  A. Lichtenstein,et al.  The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. , 1994, Blood.

[27]  A. Shad,et al.  Lymphocyte depletion during treatment with intensive chemotherapy for cancer. , 1994, Blood.

[28]  S. Heimfeld,et al.  Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin , 1994 .

[29]  M. Kosaka,et al.  Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies , 1994, British journal of haematology.

[30]  Rill,et al.  Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. , 1994, Blood.

[31]  D. Rubinstein,et al.  Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. , 1994, Cancer research.

[32]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[33]  S. Heimfeld,et al.  Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. , 1994, Blood.

[34]  F. Dreyfus,et al.  Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high‐dose chemotherapy , 1993, British journal of haematology.

[35]  D. Reece,et al.  Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. , 1993, Bone marrow transplantation.

[36]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[37]  M. Cairo,et al.  Immunomagnetic separation of CD34+ cells from human bone marrow, cord blood, and mobilized peripheral blood. , 1993, Journal of hematotherapy.

[38]  B. Ness,et al.  Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. , 1992, Blood.

[39]  L. Pilarski,et al.  Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. , 1992, Hematology/oncology clinics of North America.

[40]  G. Kandel,et al.  Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. , 1992, Bone marrow transplantation.

[41]  W. Gregory,et al.  Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Martiat,et al.  Follow‐up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome , 1991, British journal of haematology.

[43]  J. Szer,et al.  GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. , 1991, Australian and New Zealand journal of medicine.

[44]  I. Weissman,et al.  Clonal analysis of hematopoietic stem-cell differentiation in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Ritz,et al.  Monoclonal Antibody-Purged Autologous Bone Marrow Transplantation Therapy for Multiple Myeloma , 1991 .

[46]  L. Lum.  Immune recovery after bone marrow transplantation. , 1990, Hematology/oncology clinics of North America.

[47]  B. Barlogie,et al.  VAD‐based regimens as primary treatment for multiple myeloma , 1990, American journal of hematology.

[48]  A. Newland,et al.  INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA , 1989, The Lancet.

[49]  T. Tötterman,et al.  Regeneration of functional and activated NK and T sub-subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3-color FACS analysis. , 1989, Leukemia.

[50]  R. Bast,et al.  ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD‐DOSE CHEMOTHERAPY OR HIGH‐DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORT , 1988, Transplantation.

[51]  I. Weissman,et al.  Purification and characterization of mouse hematopoietic stem cells. , 1988, Science.

[52]  P. Hokland,et al.  NATURAL KILLER FUNCTION FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION: VERY EARLY REEMERGENCE BUT STRONG DEPENDENCE OF CYTOMEGALOVIRUS INFECTION , 1988, Transplantation.

[53]  A. Goldstone,et al.  Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and with chemotherapy only , 1986, British journal of haematology.

[54]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[55]  N. Abdou,et al.  The monoclonal nature of lymphocytes in multiple myeloma. Effects of therapy. , 1975, Annals of internal medicine.

[56]  S. Hammarström,et al.  Monoclonal lymphocyte population in human plasma cell myeloma. , 1974, Clinical and experimental immunology.